Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling

An, 2017, pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase, Nat. Commun., 8, 15398, 10.1038/ncomms15398

An, 2018, Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs, EBioMedicine, 36, 553, 10.1016/j.ebiom.2018.09.005

Basso, 2002, Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function, J. Biol. Chem., 277, 39858, 10.1074/jbc.M206322200

Blake, 2012, Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors, J. Med. Chem., 55, 8110, 10.1021/jm301024w

Brand, 2018, Homolog-selective degradation as a strategy to probe the function of CDK6 in AML, Cell Chem Biol., 26, 300, 10.1016/j.chembiol.2018.11.006

Brown, 2017, Maximising the potential of AKT inhibitors as anti-cancer treatments, Pharmacol. Ther., 172, 101, 10.1016/j.pharmthera.2016.12.001

Cai, 2012, Functional characterisation of a natural androgen receptor missense mutation (N771H) causing human androgen insensitivity syndrome, Andrologia, 44, 523, 10.1111/j.1439-0272.2011.01219.x

Cantley, 1999, New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway, Proc. Natl. Acad. Sci. U S A, 96, 4240, 10.1073/pnas.96.8.4240

Churcher, 2018, Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?, J. Med. Chem., 61, 444, 10.1021/acs.jmedchem.7b01272

Cromm, 2018, Addressing kinase-independent functions of Fak via PROTAC-mediated degradation, J. Am. Chem. Soc., 140, 17019, 10.1021/jacs.8b08008

Cross, 1995, Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B, Nature, 378, 785, 10.1038/378785a0

Degtyarev, 2008, Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents, J. Cell Biol., 183, 101, 10.1083/jcb.200801099

Do, 2015, Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer, Invest. New Drugs, 33, 720, 10.1007/s10637-015-0212-z

Dobrovolsky, 2018, Bruton's tyrosine kinase degradation as a therapeutic strategy for cancer, Blood, 133, 952, 10.1182/blood-2018-07-862953

Donovan, 2018, Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome, Elife, 7, 10.7554/eLife.38430

Farnaby, 2019, BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design, Nat. Chem. Biol., 15, 672, 10.1038/s41589-019-0294-6

Fruman, 2017, The PI3K pathway in human disease, Cell, 170, 605, 10.1016/j.cell.2017.07.029

Hafner, 2017, Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics, Sci. Data, 4, 170166, 10.1038/sdata.2017.166

Han, 2019, Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer, J. Med. Chem., 62, 941, 10.1021/acs.jmedchem.8b01631

Huck, 2017, Recent progress towards clinically relevant ATP-competitive Akt inhibitors, Bioorg. Med. Chem. Lett., 27, 2838, 10.1016/j.bmcl.2017.04.090

Jansen, 2016, Is there a future for AKT inhibitors in the treatment of cancer?, Clin. Cancer Res., 22, 2599, 10.1158/1078-0432.CCR-16-0100

Keppler-Noreuil, 2019, Pharmacodynamic study of miransertib in individuals with Proteus syndrome, Am. J. Hum. Genet., 104, 484, 10.1016/j.ajhg.2019.01.015

Koseoglu, 2007, AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines, Cancer Biol. Ther., 6, 755, 10.4161/cbt.6.5.3995

Kronke, 2015, Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS, Nature, 523, 183, 10.1038/nature14610

Kronke, 2014, Lenalidomide induces degradation of IKZF1 and IKZF3, Oncoimmunology, 3, e941742, 10.4161/21624011.2014.941742

Lin, 2013, Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models, Clin. Cancer Res., 19, 1760, 10.1158/1078-0432.CCR-12-3072

Manning, 2017, AKT/PKB signaling: navigating the network, Cell, 169, 381, 10.1016/j.cell.2017.04.001

McAlister, 2014, MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes, Anal Chem., 86, 7150, 10.1021/ac502040v

Meric-Bernstam, 2012, PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors, Clin. Cancer Res., 18, 1777, 10.1158/1078-0432.CCR-11-2123

Nowak, 2018, Plasticity in binding confers selectivity in ligand-induced protein degradation, Nat. Chem. Biol., 14, 706, 10.1038/s41589-018-0055-y

Oliveira, 2019, FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer, Ann. Oncol., 10.1093/annonc/mdz177

Olson, 2018, Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation, Nat. Chem. Biol., 14, 163, 10.1038/nchembio.2538

Ritchie, 2015, Limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res., 43, e47, 10.1093/nar/gkv007

Shayesteh, 1999, PIK3CA is implicated as an oncogene in ovarian cancer, Nat. Genet., 21, 99, 10.1038/5042

Silva, 2019, Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models, Elife, 8, 10.7554/eLife.45457

Soucy, 2009, Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer, Clin. Cancer Res., 15, 3912, 10.1158/1078-0432.CCR-09-0343

Stottrup, 2016, Upregulation of AKT3 confers resistance to the AKT inhibitor MK2206 in breast cancer, Mol. Cancer Ther., 15, 1964, 10.1158/1535-7163.MCT-15-0748

Team, 2013

Toker, 2012, Achieving specificity in Akt signaling in cancer, Adv. Biol. Regul., 52, 78, 10.1016/j.advenzreg.2011.09.020

Turner, 2019, Ann. Oncol., 30, 774, 10.1093/annonc/mdz086

Uhlenbrock, 2019, Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt, Chem. Sci., 10, 3573, 10.1039/C8SC05212C

Vivanco, 2014, A kinase-independent function of AKT promotes cancer cell survival, Elife, 3, 10.7554/eLife.03751

Vlietstra, 1998, Frequent inactivation of PTEN in prostate cancer cell lines and xenografts, Cancer Res., 58, 2720

Wang, 2012, Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway, Cell Signal., 24, 17, 10.1016/j.cellsig.2011.08.010

Winter, 2015, DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation, Science, 348, 1376, 10.1126/science.aab1433

Zhou, 2018, Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression, J. Med. Chem., 61, 462, 10.1021/acs.jmedchem.6b01816